STATResearch Highlights

Spyre Therapeutics IBD Drug Shows Promise in Phase 2 Trial

13 Apr 20264 min read0 viewsVerified Feed

GIST

An inflammatory bowel disease treatment developed by Spyre Therapeutics succeeded in its first major test, setting the company up to compete with several large drugmakers developing new medicines for the chronic digestive condition.  Spyre is currently running a Phase 2 trial testing three experimental ulcerative colitis drugs as standalone treatments and, eventually, as combination therapies. The company released the first batch of results Monday on one of the treatments, showing it was safe and met the primary goal of the study.  The therapy, SPY001, targets the alpha 4 beta 7 inflammation pathway, one of the emerging avenues drugmakers are probing to reduce inflammation in the gut.

In Spyre’s SKYLINE study, subjects taking SPY001 saw a 9.2 point decrease in a disease activity index. Approximately 40% of the trial subjects went into remission after 12 weeks of use.  Continue to STAT+ to read the full story...

Clinical Editorial

Study design and purpose

Reported as a Phase 2 trial ( SKYLINE) evaluating three experimental ulcerative colitis agents by Spyre Therapeutics, initially focusing on SPY001 as a standalone therapy with potential future combination approaches.

Intervention and target

SPY001 is designed to modulate the alpha 4 beta 7 inflammation pathway, an explored target for reducing gut inflammation in inflammatory bowel disease.

Primary results and status

Specific numerical outcomes are provided below.

In the first batch of results released, SPY001 demonstrated safety and achieved the study’s primary endpoint.

Efficacy signals

Within the trial cohort, a 9.2-point reduction was observed on a disease activity index after treatment.
Approximately 40% of participants achieved remission at 12 weeks of therapy.

Context and limitations

The report describes a single treatment arm within a multi-agent Phase 2 program, with results noted for one of the three experimental therapies.
Details beyond the reported outcomes, including full statistical analyses, additional endpoints, and long-term safety, are not provided in the excerpt.